Orpha Labs AG Initiates Compassionate Use Program for ORL-101 in Leukocyte Adhesion Deficiency Type II (LAD-II)
(0) First Patient to Receive ORL-101 in Israel This Week BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL -101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel formulation of an ultra-pure L-fucose currently in development for the treatment of LAD II patients. The Israeli Ministry of Health (MOH) approved the use of ORL-101 for LAD-II patients under Orpha...
Kostenloser Wertpapierhandel Bugra Basat Israeli Ministry Of Health Orpha Lab Founder Orpha Lab First Patient
Source: finanznachrichten.de